CD19 and hematopoietic and lymphoid cell neoplasm: While CD19/CD20/CD33 remain major targets for hematological cancers, CAR-NK cells have demonstrated efficacy against solid cancer targets, such as Her2, EpCAM, and EGFR, offering a broader spectrum of applicability (82–85).